Results 21 to 30 of about 321,265 (263)

The prevalence of substance use disorders and substance use in anorexia nervosa: a systematic review and meta-analysis

Journal of Eating Disorders, 2021
Aim Individuals with anorexia nervosa (AN) often present with substance use and substance use disorders (SUDs). However, the prevalence of substance use and SUDs in AN has not been studied in-depth, especially the differences in the prevalence of SUDs ...
Daniel J. Devoe, Gina Dimitropoulos, Alida Anderson, Anees Bahji, Jordyn Flanagan, Andrea Soumbasis, Scott B. Patten, Tom Lange, Georgios Paslakis   +8 more
doaj   +1 more source

Partnering with persons in long-term recovery from substance use disorder: experiences from a collaborative research project

Harm Reduction Journal, 2019
Background Traditional research about substance use disorder (SUD) treatment is considered, among an increasing number of service users, to be disempowering and poorly reflective of their priorities.
Henning Pettersen, Morten Brodahl, Jeanette Rundgren, Larry Davidson, Ingrid Amalia Havnes   +4 more
doaj   +1 more source

State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements

Drug and Alcohol Dependence Reports, 2023
Background: In 2021, the Department of Health and Human Services released guidelines allowing waiver-eligible providers seeking to treat up to 30 patients to be exempt from waiver training (WT) and the counseling and other ancillary services (CAS ...
Anita Silwal, Jeffery Talbert, Robert M. Bohler, Jordan Kelsch, Christopher Cook, Derek Blevins, Molly Gallivan, Timothy Hunt, Sarah M. Hatcher, Cindy Parks Thomas, Soncere Williams, Laura Fanucchi, Michelle R. Lofwall   +12 more
doaj   +1 more source

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman, Katherine K. Matthay, Fabienne Hollinger, Catriona Black, Ann A. Lazar, Miguel Pampaloni, Steven G. DuBois, Kieuhoa T. Vo   +7 more
wiley   +1 more source

Comparison of mortality and causes of death between treatment-engaged individuals with severe alcohol or opioid use disorder: a prospective 19-year clinical cohort study

BMC Psychiatry
Background Comparisons of long-term mortality between alcohol-use-disorder (AUD) and opioid-use-disorder (OUD) groups within clinical cohorts are scarce.
Ivar Skeie, Anne Berit Bech, Thomas Clausen, Arne Jan Hjemsæter, Anne Signe Landheim, Bent Monsbakken, Magne Thoresen, Helge Waal   +7 more
doaj   +1 more source

Medications for Substance Use Disorders [PDF]

Social Work in Public Health, 2013
In this article, the authors briefly review the pharmacotherapeutic agents that are currently available for the treatment of substance use disorders. Nicotine replacement therapies are most effective for tobacco cessation. Naltrexone, acamprosate, and disulfiram are effective for reducing alcohol use. The most effective pharmacotherapies for opiate use
Antoine B, Douaihy, Thomas M, Kelly, Carl, Sullivan   +2 more
openaire   +2 more sources

Hospitalization Through Families’ Eyes: Comparing Inpatient Care Quality for Children With Sickle Cell Disease and Cystic Fibrosis in Canada

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Sickle cell disease (SCD) is a chronic, inherited hemoglobinopathy that requires frequent hospitalization for disease‐related complications. Canadian data on inpatient care is limited. This study compared caregiver‐reported hospital experiences of children with SCD to those with cystic fibrosis (CF), a chronic, autosomal recessive ...
Hailey M. Zwicker, Kyle Kemp, Perri Tutelman, Sharon H. J. Hou, Paul Fairie, Maria Santana, Gregory M. T. Guilcher, Taryn Fay‐McClymont, Glenda Bendiak, Wendy Pelletier, Nicola Wright, Fiona Schulte   +11 more
wiley   +1 more source

Peer-delivered harm reduction and recovery support services: initial evaluation from a hybrid recovery community drop-in center and syringe exchange program

Harm Reduction Journal, 2018
Background Recovery from substance use disorder (SUD) is often considered at odds with harm reduction strategies. More recently, harm reduction has been categorized as both a pathway to recovery and a series of services to reduce the harmful consequences
Robert D. Ashford, Brenda Curtis, Austin M. Brown   +2 more
doaj   +1 more source

The Role of Hematopoietic Cell Transplantation in Ataxia‐Telangiectasia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Ataxia‐telangiectasia (A‐T) is a DNA repair disorder characterized by neurodegeneration, immunodeficiency, and cancer predisposition. Hematopoietic cell transplantation (HCT) is an established therapy in related disorders such as Fanconi anemia (FA) and Nijmegen breakage syndrome (NBS), but its role in A‐T is unclear.
Laila Alkhouli, Seth Rotz, Masatoshi Takagi, Richa Sharma   +3 more
wiley   +1 more source

Improving social functioning in people with substance use and mental health disorders using virtual reality (ROPVR): study protocol for a multi-center, pragmatic randomized controlled trial

Trials
Background In individuals with substance use disorders (SUDs), impairment of social, occupational, and/or recreational functioning is common. Social functioning encompasses social skills, social behavior, and cognitive skills, which are relevant for ...
Anne Berit Bech, Theresa Friederike Wechsler, Andreas Mühlberger, Lars Lien, Marja Leonhardt   +4 more
doaj   +1 more source